Comparison between standard and reduced volume radiotherapy in bladder preservation trimodality protocol for muscle-invasive bladder cancer patients

被引:11
|
作者
Arafat, Waleed [1 ,2 ,3 ]
Darwish, Azza [1 ]
Naoum, George E. [2 ]
Sameh, Wael [4 ]
El Husseiny, Gamal [1 ]
Abd-El-Gawad, Fathy [1 ]
Samir, Mostafa [2 ]
机构
[1] Univ Alexandria, Fac Med, Oncol Dept, Alexandria, Egypt
[2] Alexandria Comprehens Canc Ctr, Alexandria, Egypt
[3] Univ Alabama Birmingham, 1720 2nd Ave S, Birmingham, AL 35233 USA
[4] Univ Alexandria, Urol Dept, Fac Med, Alexandria, Egypt
来源
ECANCERMEDICALSCIENCE | 2016年 / 10卷
关键词
bladder cancer; lymph nodes; radiotherapy; trimodality protocol;
D O I
10.3332/ecancer.2016.682
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Aim: Our aim is to compare the toxicity, pelvic nodal relapse, and overall survival of whole bladder irradiation only to the standard technique of whole pelvis irradiation followed by bladder boost in patients with muscle-invasive bladder carcinoma undergoing bladder preservation protocol. Material and method: A total of 60 patients with transitional cell carcinoma, stage T2-3, N0, M0 bladder cancer were subjected to maximal transurethral resection bladder tumour (TURB). Then, the patients were randomised into two groups: group I (30 patients) to receive whole pelvis radiotherapy 44 Gy followed by 20 Gy bladder boost. While group II (30 patients) were randomised to receive whole bladder radiotherapy alone for a total dose of 64 Gy. In both groups, concomitant cisplatin and paclitaxel were given weekly throughout the whole course of radiotherapy where conventional 2 Gy/fraction were used. Additionally, four cycles of adjuvant cisplatin and paclitaxel were given after the end of the chemoradiotherapy induction course. Results: The first assessment after the induction chemoradiotherapy showed that complete response was achieved in 73.3% of patients in group I and 76.7% of the patients in group II. After a median follow-up of 2 years, regional relapse occurred in 7.1% of patients in group I and 10.3% in group II. (p = 1). Distant metastases were detected in 17.9% of patient in group I and 13.8% in group II (p = 0.73). The 2-year disease-free survival was 60% in group I and 63.3% in group II (p = 0.79). The whole 2-year overall survival was 75% in group I and 79.3% in group II (p = 0.689). Radiation gastrointestinal (GI) acute toxicity was higher in group I than in group II (p = 0.001), while late GI radiation toxicity was comparable in both groups. Conclusion: Treating the bladder only, without elective pelvic nodal irradiation, did not compromise pelvic control rate, but significantly decreased the acute radiation toxicity.
引用
收藏
页数:13
相关论文
共 50 条
  • [41] Contemporary and Emerging Approaches to Bladder-Preserving Trimodality Therapy for Muscle-Invasive Bladder Cancer
    Konieczkowski, David J.
    Efstathiou, Jason A.
    Mouw, Kent W.
    HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA, 2021, 35 (03) : 567 - 584
  • [43] Impact of sarcopenia in bladder preservation therapy for muscle-invasive bladder cancer patients: a narrative review
    Fukushima, Hiroshi
    Koga, Fumitaka
    TRANSLATIONAL ANDROLOGY AND UROLOGY, 2022, : 1433 - 1441
  • [44] Radiotherapy plus Chemotherapy in Muscle-Invasive Bladder Cancer
    Chung, Shiu-Dong
    Huang, Chao-Yuan
    Yu, Hong-Jeng
    NEW ENGLAND JOURNAL OF MEDICINE, 2012, 367 (04): : 379 - 379
  • [45] Radiotherapy With or Without Chemotherapy in Muscle-invasive Bladder Cancer
    Bagrodia, Aditya
    Lotan, Yair
    EUROPEAN UROLOGY, 2013, 63 (03) : 580 - 581
  • [46] Radiotherapy with or without Chemotherapy in Muscle-Invasive Bladder Cancer
    James, Nicholas D.
    Hussain, Syed A.
    Hall, Emma
    Jenkins, Peter
    Tremlett, Jean
    Rawlings, Christine
    Crundwell, Malcolm
    Sizer, Bruce
    Sreenivasan, Thiagarajan
    Hendron, Carey
    Lewis, Rebecca
    Waters, Rachel
    Huddart, Robert A.
    NEW ENGLAND JOURNAL OF MEDICINE, 2012, 366 (16): : 1477 - 1488
  • [47] Editorial comment: bladder preservation as a treatment strategy in muscle-invasive bladder cancer
    Ajib, Khaled
    Kulkarni, Girish S.
    TRANSLATIONAL ANDROLOGY AND UROLOGY, 2018, 7 : S723 - S726
  • [48] Concomitant chemoradiotherapy for muscle-invasive bladder cancer: The way forward for bladder preservation?
    Sherwood, BT
    Jones, GDD
    Mellon, JK
    Kockelbergh, RC
    Steward, WP
    Symonds, RP
    CLINICAL ONCOLOGY, 2005, 17 (03) : 160 - 166
  • [49] A balanced perspective on bladder preservation and systemic treatment in muscle-invasive bladder cancer
    Lin, Fu-Xiang
    Wang, Lei
    Xu, Zhan-Ping
    WORLD JOURNAL OF UROLOGY, 2024, 42 (01)
  • [50] The Role of Neoadjuvant Chemotherapy in Bladder Preservation Approaches in Muscle-Invasive Bladder Cancer
    Stecca, Carlos
    Mitin, Timur
    Sridhar, Srikala S.
    SEMINARS IN RADIATION ONCOLOGY, 2023, 33 (01) : 51 - 55